Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy

Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) improves the overall survival of patients with EGFR-mutated non-small-cell lung cancer (NSCLC). First-generation EGFR-TKIs (e.g., gefitinib and erlotinib) or second-generation EGFR-TKIs (e.g., afatinib and dacomit...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagano, Tatsuya, Tachihara, Motoko, Nishimura, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262543/
https://www.ncbi.nlm.nih.gov/pubmed/30445769
http://dx.doi.org/10.3390/cells7110212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262543/
https://www.ncbi.nlm.nih.gov/pubmed/30445769
http://dx.doi.org/10.3390/cells7110212

Ejemplares similares